Today, Boehringer Ingelheim announced that results from a Phase I study demonstrate its bevacizumab biosimilar candidate, “BI 695502,” is bioequivalent to Avastin®.
According to the announcement, BI 695502 met all the pre-defined primary and secondary endpoints in Boehringer Ingelheim’s “INVICTAN®-1″ study, with no clinically relevant differences in safety or immunogenicity found between the study’s BI 695502 and Avastin® treatment groups.
The press release also states that a Phase III study, “INVICTAN®-2,” is currently underway to evaluate the efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Stay tuned to the Big Molecule Watch for additional developments.
